ReviewJournal of immunology research2021
CAR T-Cell Production Using Nonviral Approaches.
Review in Journal of immunology research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 61 citations in OpenAlex.
- Pathology associated with human CAR T cell administration in NOD.Cg-Veterinary pathology · 2026Article
- Recent advances in lipid and biomimetic nanocarriers for nucleic acid delivery in glioblastoma.Discover oncology · 2026Review
- Imaging CRISPR-edited CAR-T cell therapies with optical and positron emission tomography reporters.Theranostics · 2026Article
- Nanoparticle-based strategy in CAR-T cell immunotherapy: challenges, implications, and perspectives.Molecular cancer · 2025Review
- Preclinical efficacy of multi-targeting mRNA-based CAR T cell therapy in resection models of glioblastoma.Molecular therapy. Nucleic acids · 2025Article
- CAR T-cell therapy in hematologic and solid malignancies: mechanisms, clinical applications, and future directions.Medical oncology (Northwood, London, England) · 2025Review
- Colorectal Cancer; Novel Approaches in Chimeric Antigen Receptors (CAR) -T cell.International journal of molecular and cellular medicine · 2025Review
- New player in CAR-T manufacture field: comparison of umbilical cord to peripheral blood strategies.Frontiers in immunology · 2025Review
- Cas9-induced targeted integration of large DNA payloads in primary human T cells via homology-mediated end-joining DNA repair.Nature biomedical engineering · 2024Article
- Titrating chimeric antigen receptors on CAR T cells enabled by a microfluidic-based dosage-controlled intracellular mRNA delivery platform.Biomicrofluidics · 2024Article
- Revolutionizing cancer treatment: an in-depth exploration of CAR-T cell therapies.Medical oncology (Northwood, London, England) · 2024Review
- Advanced strategies in improving the immunotherapeutic effect of CAR-T cell therapy.Molecular oncology · 2024Review
- Expanding applications of allogeneic platelets, platelet lysates, and platelet extracellular vesicles in cell therapy, regenerative medicine, and targeted drug delivery.Journal of biomedical science · 2023Review
- Nanoparticle-Based Chimeric Antigen Receptor Therapy for Cancer Immunotherapy.Tissue engineering and regenerative medicine · 2023Review
- Non-viral chimeric antigen receptor (CAR) T cells going viral.Immuno-oncology technology · 2023Review
- CAR T Cell Therapy: A Versatile Living Drug.International journal of molecular sciences · 2023Review
- Targeting B Cell Maturation Antigen in Patients with Multiple Myeloma: Current Perspectives.OncoTargets and therapy · 2023Review
- From barriers to novel strategies: smarter CAR T therapy hits hard to tumors.Frontiers in immunology · 2023Review
- Cell Squeeze: driving more effective CD8 T-cell activation through cytosolic antigen delivery.Immuno-oncology technology · 2022Review
- Immunotherapy and immunoengineering for breast cancer; a comprehensive insight into CAR-T cell therapy advancements, challenges and prospects.Cellular oncology (Dordrecht, Netherlands) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chimeric antigen receptor T-cells (CAR T-cells) represent a novel and promising approach in cancer immunotherapy. According to the World Health Organization (WHO), the number of oncological patients is steadily growing in developed countries despite immense progress in oncological treatments, and the prognosis of individual patients is still relatively poor. Exceptional results have been recorded for CAR T-cell therapy in patients suffering from B-cell malignancies. This success opens up the possibility of using the same approach for other types of cancers. To date, the most common method for CAR T-cell generation is the use of viral vectors. However, dealing with virus-derived vectors brings possible obstacles in the CAR T-cell manufacturing process owing to strict regulations and high cost demands. Alternative approaches may facilitate further development and the transfer of the method to clinical practice. The most promising substitutes for virus-derived vectors are transposon-derived vectors, most commonly sleeping beauty, which offer great coding capability and a safe integration profile while maintaining a relatively low production cost. This review is aimed at summarizing the state of the art of nonviral approaches in CAR T-cell generation, with a unique perspective on the conditions in clinical applications and current Good Manufacturing Practice. If CAR T-cell therapy is to be routinely used in medical practice, the manufacturing cost and complexity need to be as low as possible, and transposon-based vectors seem to meet these criteria better than viral-based vectors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.